Log in

LON:RENEReNeuron Group Share Price, Forecast & News

GBX 135.70
+0.70 (+0.52 %)
(As of 06/1/2020 04:47 AM ET)
Add
Compare
Today's Range
130.10
Now: GBX 135.70
135.70
50-Day Range
130
MA: GBX 149.73
173
52-Week Range
71
Now: GBX 135.70
342
Volume1,602 shs
Average Volume28,700 shs
Market Capitalization£43.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Read More
ReNeuron Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.73 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-38198400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£6.39 million
Cash FlowGBX 60.43 per share
Book ValueGBX 63.50 per share

Profitability

Miscellaneous

Employees62
Market Cap£43.20 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

ReNeuron Group (LON:RENE) Frequently Asked Questions

How has ReNeuron Group's stock been impacted by COVID-19 (Coronavirus)?

ReNeuron Group's stock was trading at GBX 106 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RENE shares have increased by 28.0% and is now trading at GBX 135.70. View which stocks have been most impacted by Coronavirus.

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) released its quarterly earnings results on Friday, December, 6th. The company reported ($12.30) earnings per share for the quarter, topping the Zacks' consensus estimate of ($16.30) by $4.00. View ReNeuron Group's earnings history.

Has ReNeuron Group been receiving favorable news coverage?

Media coverage about RENE stock has been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ReNeuron Group earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutReNeuron Group.

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), ValiRx (VAL), Independent Oil & Gas (IOG), Dignity (DTY), Tri-star Resources (TSTR), Sirius Minerals (SXX), Collagen Solutions (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 135.70.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of £43.20 million and generates £6.39 million in revenue each year. ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.